Embolization is a minimally invasive therapy in which an embolus is injected to stop bleeding or to cut off the supply of blood to a tumor in order to shrink it for preparation of its removal. Embolization is used in various interventional radiology procedures. In this procedure, an interventional radiologist uses image guidance to insert the catheter into a primary artery and advance it to vessel leading to a tumor or other part where the blood supply needs to be blocked. Embolization is an option for some patients with tumors that cannot be removed by surgery. It can be used for tumors that are usually larger than 5 cm thickness and cannot be removed by ablation. This procedure is used to treat various types of cancerous tumors, hemorrhages, along with the management of malignant hypertension caused by renal failure.
Embolization procedure uses various types of embolization particles such as radioembolization spheres, microspheres, drug eluting beads, PVA particles, gelfoam particles, and other particles. These particles are used in different procedures such as liver cancer, metastatic cancer in the liver, kidney cancer, neuroendocrine tumors, uterine fibroids, and aneurysms. These particles are highly used in the treatment of various types of cancers whose prevalence has been increasing across the globe.
Embolization Particle Market - Market Dynamics
The market for embolization particle is driven by factors such as increasing prevalence of various types of cancer.
Embolization particles are the crucial product used in the treatment of malignancies such as cancer, peripheral diseases, and others. Rising prevalence of cancer globally, has supported growth of the embolization particle market. According to World Health Organization (WHO), cancer is the second prominent cause of death across the globe, and around 9.6 million deaths occurred due to cancer in 2018. Moreover, as per the Cancer Research UK, over 17 million new cases were estimated to occur in year 2018 around the globe. The burden of cancer is increasing rapidly in the U.S. with the incidence of 439.2 per 100,000 men and women per year as according to National Cancer Institute (2015).
Moreover, major players are constantly introducing technologically advanced products with improved efficiency that supports growth of the embolization particle market. For instance, in 2017, Sirtex introduced SIR-Spheres Y-90 resin microspheres, which serves as first-line treatment for patients with liver metastases from right-sided primary colon cancer. In 2016, UK National Institute for Health and Care Excellence (NICE) issued a new update stating that National Health Service (NHS) doctors and commissioners may consider Sirtex’s SIR-Spheres Y-90 resin microspheres as an alternative to standard therapy with trans-arterial chemoembolization (TACE) or sorafenib in the treatment of patients with inoperable primary liver cancer.
However, lesser number of interventional neuroradiologists and interventional neuroradiology (INR) labs across the globe and stringent regulations for embolization particle approvals are some of the major factors restraining growth of the global embolization particle market.
Embolization Particle Market – Regional Insights
On the basis of geography, the global embolization particle market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America would be dominant region in the global embolization particle market in 2017. This is owing to the strong economic condition, huge expansion of healthcare domain, and increasing focus of research institutions on modernizing technology for new and advanced diagnosis and treatment methods. Moreover, unique hospital infrastructures, and availability of skilled healthcare professionals is further aiding growth of the market.
On the other hand, Asia Pacific is expected to witness significant growth in embolization particle market during the forecast period, owing to increasing patient population (mainly cancer) in emerging economies such as India. For instance, according to Indian Council Medical Research (ICMR), it is expected that over 17.3 lakh new cancer cases and over 8.8 lakh deaths will occur in India due to cancer by 2020. Moreover, growing focus by government on enhancing healthcare facilities and booming medical tourism is expected to boost growth of the embolization particle market in this region.
Embolization Particle Market – Competitive Landscape
Major players operating in the embolization particle markets include, Abbott Laboratories, Boston Scientific Corporation, BTG plc, Cook Medical, Inc., Edwards Lifesciences, Johnson & Johnson, Pfizer, Inc., Sirtex Medical Limited, St. Jude Medical, Inc., and Terumo Corporation.
Key players are focusing on mergers & acquisitions and new product launches in order to retain dominant position in the market. For instance, in November 2018, Boston Scientific announced it plans to acquire BTG plc is a global healthcare company focused on interventional medicine. This will help the company to develop and commercialize products used in minimally-invasive procedures targeting cancer and vascular diseases
Embolization Particle Market Taxonomy
On the basis of product type, the global embolization particle market is segmented into:
- Radioembolization Spheres
- Drug Eluting Beads
- PVA Particles & Gelfoam Particles
- Other Particles
On the basis of application, the global embolization particle market is segmented into:
- Peripheral Vascular Disease
On the basis of end-user, the global embolization particle market is segmented into:
- Hospitals & Clinics
- Ambulatory Centers
On the basis of treatment, the global embolization particle market is segmented into:
- Urethral Dilation
- Direct Vision Internal Urethrotomy (DVIU)
On the basis of geography, the global embolization particle market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East